Diamyd Medical - Developing therapies for type 1 diabetes

Press Releases

March 4, 2021

Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd^®

Events & Mediawatch

January 20, 2021 Sweden

di.se: Q1 rapportkommentar i DI Börsmorgon

Calendar

Data pager
Data pager
1 2

March 11 − March 12, 2021

SSSD 2021

Scandinavian Society for the Study of Diabetes, 2021 virtual conference

March 11, 2021

Erik Penser Bank Corporate Market Day

Company presentation by CEO Ulf Hannelius.

March 31, 2021

Quarterly Report II

Quarterly Report 2 2020/2021

April 13 − April 14, 2021

Drug Discovery & Development with AI & ML

3rd Annual Forum - Online Conference

Financial Reports

January 20, 2021
Quarterly Report I 20/21

Company Presentation

February 8, 2021

The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 1 20/21

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 463 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research

ORDER

©

Privacy Policy | Cookie Policy

Share This Page

GAD PRODUCTS

Order GAD for preclinical research